Intent to focus on the first-ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets. More: Spark, Novartis tie up in gene therapy licensing deal worth up to 0M Source: fierce
read moreSome Allergan investors have felt queasy about the potential for Botox knockoffs to suck up some of the company’s bottom line. But manufacturing issues for one of those players, Evolus, could delay approval of its candidate. More: Evolus says its
read moreNovartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million. More: Novartis buys access to Spark’s vision loss therapy Source: News
read moreThe Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS). More: Lancet-published data show potential of GW’s Epidiolex Source: News
read moreBrilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack. More: AZ enrolls first patient in Brilinta stroke trial Source: News
read moreFinal guidelines have now been published endorsing NHS use of Novartis’ Zykadia as a first line of attack for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), offering patients a new treatment option. More: First-line use of lung cancer
read more© 1994 - 2026 B.M. Pharmaceuticals